SOUTH SAN FRANCISCO, Calif., May 30, 2024 /PRNewswire/ — Enable Biosciences Inc. has been awarded a patent for a cutting-edge method of detecting polyclonal antibodies, marking a significant advancement in diagnostic technologies, particularly in assessing the risk of Type 1 Diabetes (T1D).

The EU Medical Device Regulation CE certification approves that the most common types of skin cancer and a wide range of skin diseases and conditions can be treated in less than 90 seconds.